Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.

作者信息

Johnson Philip James, Pinato David J, Kalyuzhnyy Anton, Toyoda Hidenori

机构信息

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.

Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom.

出版信息

J Clin Oncol. 2022 Jul 1;40(19):2078-2082. doi: 10.1200/JCO.21.02373. Epub 2022 Mar 28.

DOI:10.1200/JCO.21.02373

PMID:35344390

Abstract

摘要

相似文献

[1]

Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.

J Clin Oncol. 2022-7-1

[2]

Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.

Exp Biol Med (Maywood). 2017-11-29

[3]

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.

Clin Transl Oncol. 2012-8-9

[4]

Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis .

Int J Clin Pharmacol Ther. 2017-6

[5]

Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.

J BUON. 2017

[6]

Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma.

BMC Cancer. 2016-5-31

[7]

[Advanced hepatocellular carcinoma: importance of clinical trials].

Rev Med Suisse. 2015-5-20

[8]

Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?

J Gastrointest Cancer. 2010-12

[9]

Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.

Expert Rev Anticancer Ther. 2012-10-24

[10]

Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?

Future Oncol. 2015

引用本文的文献

[1]

CKAP4 and PLOD2 as novel prognostic biomarkers in hepatocellular carcinoma: a proteomics-driven risk stratification model.

Front Cell Dev Biol. 2025-7-2

[2]

Unexplained Leg Swelling Leading to a Diagnosis of Hepatocellular Carcinoma: A Case Report.

Cureus. 2025-5-16

[3]

Assessment of ghrelin serum level and gene polymorphism as a risk factor in progression of chronic viral hepatitis.

Sci Rep. 2025-5-8

[4]

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.

JHEP Rep. 2024-12-5

[5]

Spleen volume is associated with overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with portal hypertension.

World J Gastrointest Surg. 2024-7-27

[6]

Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.

Oncologist. 2024-11-4

[7]

Association of easy albumin-bilirubin score with increased mortality in adult trauma patients.

Front Surg. 2024-4-24

[8]

ALBI score combined with FIB-4 index to predict post-hepatectomy liver failure in patients with hepatocellular carcinoma.

Sci Rep. 2024-4-5

[9]

Evaluation of the Easy Albumin-Bilirubin Score as a Prognostic Tool for Mortality in Adult Trauma Patients in the Intensive Care Unit: A Retrospective Study.

Diagnostics (Basel). 2023-11-15

[10]

CK2B is a Prognostic Biomarker and a Potential Drug Target for Hepatocellular Carcinoma.

Recent Pat Anticancer Drug Discov. 2024

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献